PURE Bioscience, Inc. reported fiscal second‑quarter 2026 results for the period ended January 31 2026, showing net product sales of $443,000, a 13.3% increase from $391,000 in the same quarter of 2025. The rise was driven by stronger demand from the company’s food‑processing customer base, which expanded its use of the proprietary Silver Dihydrogen Citrate (SDC) antimicrobial technology.
Earnings per share remained flat at $(0.01), unchanged from the prior year’s quarter. The company’s operating loss widened slightly to $1.487 million for the six‑month period ended January 31 2026, compared with a $1.487 million loss for the same period in 2025. The increase in loss was largely attributable to higher cost of goods sold and continued investment in research and development, while selling, general, and administrative expenses fell due to reductions in board fees and personnel costs, partially offsetting higher interest expense.
Liquidity remains a critical concern. Management and auditors have expressed substantial doubt about the company’s ability to continue as a going concern without new financing. As of January 31 2026, the company reported a stockholders’ deficiency of $6.273 million and a significant amount of related‑party convertible debt. Customer concentration is also a risk, with one customer accounting for 30% of net product sales for the six‑month period.
Strategically, PURE is advancing its SDC technology beyond food safety. The company has received USDA Biobased Product Certification for its PURE Clean product and is expanding into the transportation and biomedical sectors through focused partnerships. These initiatives aim to diversify revenue streams and leverage the technology’s stability and dual‑action antimicrobial properties.
Management emphasized the company’s focus on converting in‑plant validations into recurring commercial programs and deepening its presence in the food and beverage vertical. The leadership highlighted the importance of accelerating adoption, diversifying with intention, and expanding market reach to drive sustained revenue growth, while acknowledging the need for additional capital to address liquidity constraints and support ongoing product development.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.